Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial
Journal of Diabetes · 2025-09 · 17 (9)
DOI: 10.1111/1753-0407.70152 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes, online erschienen am 05.09.2025. Verfasst von Shujing Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for …. Hauptthemen laut MEDLINE: Aspirin, Clopidogrel, Platelet Aggregation Inhibitors, Stents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd, Shanghai Clinical Research Center for Interventional Medicine, Clinical Research Special Fund of Zhongshan Hospital Fudan University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Despite increased risk of ischemic events in diabetes, the optimal anti‐thrombotic strategy for secondary prevention has not been defined. We aimed to assess the efficacy and safety of optimal antiplatelet agents such as indobufen‐based dual antiplatelet therapy (DAPT) in patients with diabetes after coronary stenting.
Methods
OPTION trial was a randomized, open‐label, noninferiority, and multicentric study in China. Enrolled subjects were randomized 1:1 to indobufen‐based DAPT or aspirin‐based DAPT. This post hoc analysis from OPTION trial was performed by the presence of diabetes. The primary endpoint was a 1‐year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium (BARC) criteria type 2, 3, or 5 bleeding.
Results
Of 4551 OPTION patients, the primary endpoint occurred in 93/1570 patients with diabetes (5.92%), as compared to 148/2981 without diabetes (4.96%) (HR: 0.72, 95% CI: 0.47–1.08, and HR: 0.73, 95% CI: 0.53–1.01, respectively), without significant interaction between diabetes status and treatment effect ( P interaction = 0.935). The secondary efficacy endpoint was comparable between patients with (HR: 1.31, 95% CI: 0.60–2.84) and without diabetes (HR: 0.95, 95% CI: 0.51–1.76) ( P interaction = 0.526). Similarly, both subgroups derived similar benefits for the safety endpoint (HR, 0.56; 95% CI, 0.34–0.92 for subjects with diabetes vs. HR, 0.66; 95% CI, 0.45–0.98 for those without diabetes; P interaction = 0.609).
Conclusions
In patients receiving DES implantation, indobufen‐based DAPT might be considered as a reasonable alternative to aspirin‐based DAPT in the secondary prevention for those with diabetes, especially in patients at high bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
- Department of Cardiology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
- Department of Infectious Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai, China.
- Department of Cardiology, Taian City Central Hospital, Taian, China.
- Department of Cardiology, Xi'an no. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, China.
ORCID-Profile: Hongyi Wu
Förderung
- Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
- Shanghai Clinical Research Center for Interventional Medicine
- Clinical Research Special Fund of Zhongshan Hospital Fudan University
- National Natural Science Foundation of China General Program
- Research Project of Shanghai Municipal Health Commission
Zitieren
APA
Wu, S., Xu, H., Xu, L., Zhang, H., Cheng, K., Wang, X., Chen, M., Li, G., Huang, J., Lan, J., Wei, G., Zhao, X., Qi, Z., Qian, J., Wu, H., Ge, J., & OPTION investigators (2025). Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial. Journal of Diabetes, 17(9). https://doi.org/10.1111/1753-0407.70152
Vancouver
Wu S, Xu H, Xu L, Zhang H, Cheng K, Wang X, et al. Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial. Journal of Diabetes. 2025;17(9). doi:10.1111/1753-0407.70152
BibTeX
@article{Wu2025,
author = {Wu, Shujing and Xu, Huajie and Xu, Lili and Zhang, Huanyi and Cheng, Kang and Wang, Xiaoyan and Chen, Manhua and Li, Guangping and Huang, Jiangnan and Lan, Jun and Wei, Guanghe and Zhao, Xin and Qi, Zhiyong and Qian, Juying and Wu, Hongyi and Ge, Junbo and OPTION investigators, OPTION investigators},
title = {Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial},
journal = {Journal of Diabetes},
year = {2025},
volume = {17},
number = {9},
doi = {10.1111/1753-0407.70152}
}
EUVIMED